Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02953678 · ClinicalTrials.gov registry record · Phase 2
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
A Phase 2 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 71
- Enrollment target
NCT02953678 is a Phase 2 study that has completed, run by Incyte Corporation. The registered enrollment target is 71 participants.
The verdict
NCT02953678, a Phase 2 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 71 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the efficacy of ruxolitinib in combination with corticosteroids in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease (GVHD).
Interventions
- DRUG Ruxolitinib
- DRUG Prednisone or methylprednisolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2016-12-30 |
| Est. Completion | 2019-08-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02953678
The ClinicalTrials.gov registry entry for NCT02953678 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT02953678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02953678 about?
NCT02953678 is a clinical study titled "A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)". The purpose of this study was to assess the efficacy of ruxolitinib in combination with corticosteroids in subjects with Grades II to IV steroid-refractory acute graft-versus-host disease (GVHD).
What is the current status of trial NCT02953678?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 71 participants. The study started on 2016-12-30. Estimated completion is 2019-08-14.
What interventions are being tested in trial NCT02953678?
The interventions under investigation include: Ruxolitinib (DRUG), Prednisone or methylprednisolone (DRUG).
Who is sponsoring clinical trial NCT02953678?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.